UnknownNot Applicable

Atorvastatin in the TREATment of Intracranial Unruptured VertebroBasilar Dissecting Aneurysms

China40 participantsStarted 2021-07-01

Plain-language summary

This study was designed to whether there is a measurable reduction in inflammation in walls of unruptured vertebrobasilar dissecting aneurysms with atorvastatin.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Be aged 18 or over, male or non-pregnant female;
✓. Patients have a unruptured vertebrobasilar dissecting aneurysm identified on imaging (CT, MRI or DSA)
✓. Patients with wall enhancement and intramural hematomas of UVBDAs by HR-VW-MRI before treatment.
✓. Patients who is able to understand the objective of the trail, agrees and signs the written informed consent form.

Exclusion criteria

✕. The aneurysm types of non-dissecting aneurysm, such as saccular aneurysms, fusiform aneurysms and traumatic aneurysms, etc.;
✕. Patients with MRI contraindications: metallic implant, contrast allergy, claustrophobia, etc.;
✕. Planned treatment of the aneurysm within 6 months;
✕. Several impaired liver or renal functions;
✕. Retreatment of recurrent aneurysm;
✕. Pregnant or lactating women;
✕. Patients with malignant diseases, such as liver disease, kidney diseases, congestive heart failure, malignant tumors, etc.;
✕. Poor compliance patients;

What they're measuring

1.Change of aneurysm wall inflammation as measured by HR-VW-MRI.

Timeframe: 6 months

Trial details

NCT IDNCT04943783

SponsorBeijing Neurosurgical Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-01-01

Contact for this trial

Mirzat Turhon, MD

+8618699158800 18699158800@163.com

View on ClinicalTrials.gov More Dissecting Aneurysm of Cerebral Artery trials